Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-2: Radiographic observations

Knut N. Leknes, Jie Yang, Mohammed Qahash, Giuseppe Polimeni, Cristiano Susin, Ulf M E Wikesjö

Research output: Contribution to journalArticlepeer-review

80 Scopus citations


Objectives: Effective carrier technologies and dosing appear critical for the successful use of bone morphogenetic proteins (BMPs). This study evaluated radiographically the potential of a purpose-designed titanium porous-oxide implant surface combined with recombinant human BMP-2 (rhBMP-2) to stimulate alveolar ridge augmentation. Material and methods: Twelve young-adult Labrador dogs were used. Three 10-mm titanium implants per jaw quadrant were placed 5 mm into the alveolar ridge following extraction of the premolar teeth and reduction of alveolar ridge. Six animals received implants coated with rhBMP-2 at 0.75 or 1.5 mg/ml randomized to contralateral jaw quadrants. Another six animals received implants coated with rhBMP-2 at 3 mg/ml or uncoated control using the same split-mouth design. The mucoperiosteal flaps were advanced, adapted, and sutured to submerge the implants. Radiographic registrations were made immediately postsurgery (baseline), and at weeks 4 and 8 (end of study). Results: rhBMP-2-coated implants exhibited robust radiographic bone formation extending to and above the implant platform from week 4 (P<0.01). Some rhBMP-2-coated implants showed voids within the newly formed bone that gradually resolved and/or implant displacement, being severe in two animals receiving implants coated with rhBMP-2 at 3 mg/ml. Controls showed limited, if any, new bone formation at weeks 4 and 8 postsurgery. There were no significant differences among the rhBMP-2 groups in bone gain. Conclusions: The titanium porous-oxide surface serves as an effective carrier for rhBMP-2, showing a clinically significant potential to stimulate local bone formation. With the carrier technology used, therapeutic dosage appears to be in the range of 0.75-1.5 mg/ml.

Original languageEnglish (US)
Pages (from-to)1027-1033
Number of pages7
JournalClinical Oral Implants Research
Issue number10
StatePublished - Oct 2008


  • BMP-2
  • Bone
  • Bone morphogenetic protein
  • Dog
  • Oral/dental implant
  • Radiology
  • Seroma
  • Tissue engineering
  • Titanium

ASJC Scopus subject areas

  • Oral Surgery


Dive into the research topics of 'Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-2: Radiographic observations'. Together they form a unique fingerprint.

Cite this